Carbetocin (PABAL) and postpartum hemorrhage (PPH)

Fouad Ech chouyekh 1, *, Badr El Marjani 2, Sofia Jayi 1, FZ Fdili Alaoui 1, Hikmat Chaara 1 and M.A Melhouf 1

1 Department of Obstetrics Gynecology II, CHU Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
2 Faculty of Letters and Human Sciences-Dhar El Mahraz-Sidi Mohamed Ben Abdellah University, Fez, Morocco.
 
Research Article
World Journal of Advanced Research and Reviews, 2023, 19(03), 428–438
Article DOI: 10.30574/wjarr.2023.19.3.1811
 
Publication history: 
Received on 30 July 2023; revised on 07 September 2023; accepted on 09 September 2023
 
Abstract: 
Objective: with the marketing in our country of the Carbetocin molecule for the prevention of postpartum hemorrhage which currently relies on the administration of Oxytocin, we tried to make a comparison of the effectiveness between the 2 products.
Method: review of the literature and studies made by comparing the 2 products.
Results: Carbetocin has been proposed in the prevention of uterine atony during Cesarean: Carbetocin (Pabal) is a synthetic analog of human oxytocin: its longer duration of action (approximately 5 hours instead of 1 hour 30 minutes for Syntocinon), and single dose make it a molecule of choice in the therapeutic strategy prevention of uterine atony.
Reliable and well-tolerated Carbetocin appears to be as effective as Oxytocin in clinical practice in preventing PPH.
 
Keywords: 
Carbetocin; Oxytocin; Uterine atony; Cesarean; Preventing PPH; Postpartum hemorrhage
 
Full text article in PDF: 
Share this